1. Home
  2. CTMX vs QNCX Comparison

CTMX vs QNCX Comparison

Compare CTMX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • QNCX
  • Stock Information
  • Founded
  • CTMX 2008
  • QNCX 2012
  • Country
  • CTMX United States
  • QNCX United States
  • Employees
  • CTMX N/A
  • QNCX N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CTMX Health Care
  • QNCX Health Care
  • Exchange
  • CTMX Nasdaq
  • QNCX Nasdaq
  • Market Cap
  • CTMX 85.3M
  • QNCX 62.0M
  • IPO Year
  • CTMX 2015
  • QNCX 2019
  • Fundamental
  • Price
  • CTMX $0.79
  • QNCX $1.40
  • Analyst Decision
  • CTMX Buy
  • QNCX Strong Buy
  • Analyst Count
  • CTMX 6
  • QNCX 4
  • Target Price
  • CTMX $5.77
  • QNCX $9.50
  • AVG Volume (30 Days)
  • CTMX 764.2K
  • QNCX 128.0K
  • Earning Date
  • CTMX 03-10-2025
  • QNCX 03-31-2025
  • Dividend Yield
  • CTMX N/A
  • QNCX N/A
  • EPS Growth
  • CTMX N/A
  • QNCX N/A
  • EPS
  • CTMX 0.16
  • QNCX N/A
  • Revenue
  • CTMX $126,617,000.00
  • QNCX N/A
  • Revenue This Year
  • CTMX $22.55
  • QNCX N/A
  • Revenue Next Year
  • CTMX N/A
  • QNCX N/A
  • P/E Ratio
  • CTMX $4.79
  • QNCX N/A
  • Revenue Growth
  • CTMX 33.66
  • QNCX N/A
  • 52 Week Low
  • CTMX $0.75
  • QNCX $0.51
  • 52 Week High
  • CTMX $5.85
  • QNCX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 40.57
  • QNCX 35.89
  • Support Level
  • CTMX $0.82
  • QNCX $1.37
  • Resistance Level
  • CTMX $0.98
  • QNCX $1.69
  • Average True Range (ATR)
  • CTMX 0.07
  • QNCX 0.12
  • MACD
  • CTMX -0.00
  • QNCX -0.02
  • Stochastic Oscillator
  • CTMX 19.35
  • QNCX 7.32

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Share on Social Networks: